Implementation of tripartite estimands using adherence causal estimators under the causal inference framework
暂无分享,去创建一个
[2] Haoda Fu,et al. A General Framework for Treatment Effect Estimators Considering Patient Adherence , 2020 .
[3] B Ratitch,et al. Recent Developments in the Prevention and Treatment of Missing Data , 2014, Therapeutic innovation & regulatory science.
[4] D. Rubin,et al. Principal Stratification in Causal Inference , 2002, Biometrics.
[5] Donald B Rubin,et al. Principal Stratification for Causal Inference With Extended Partial Compliance , 2008 .
[6] Zhi Geng,et al. Identifiability and Estimation of Causal Effects by Principal Stratification With Outcomes Truncated by Death , 2011 .
[7] J. Tukey. The Future of Data Analysis , 1962 .
[8] Donald B. Rubin,et al. Estimation of Causal Effects via Principal Stratification When Some Outcomes are Truncated by “Death” , 2003 .
[9] Avi Feller,et al. Principal Score Methods: Assumptions, Extensions, and Practical Considerations , 2017 .
[10] Y. Fong,et al. Transformation Model Choice in Nonlinear Regression Analysis of Fluorescence-Based Serial Dilution Assays , 2016, Statistics in biopharmaceutical research.
[11] P. Gilbert,et al. Sensitivity Analyses Comparing Time‐to‐Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity , 2011, Biometrics.
[12] Norbert Benda,et al. Choosing Appropriate Estimands in Clinical Trials , 2015, Therapeutic innovation & regulatory science.
[13] Max Welling,et al. Causal Effect Inference with Deep Latent-Variable Models , 2017, NIPS 2017.
[14] Tyler J VanderWeele,et al. Principal Stratification -- Uses and Limitations , 2011, The international journal of biostatistics.
[15] Heinz Schmidli,et al. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence , 2019, Statistics in medicine.
[16] Bohdana Ratitch,et al. Causal Inference and Estimands in Clinical Trials , 2020 .
[17] Thomas Permutt,et al. A taxonomy of estimands for regulatory clinical trials with discontinuations , 2016, Statistics in medicine.
[18] Björn Bornkamp,et al. Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint , 2018, Statistics in Biopharmaceutical Research.
[19] Kosuke Imai,et al. Sharp bounds on the causal effects in randomized experiments with "truncation-by-death" , 2008 .
[20] F. Travert,et al. Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 , 2016, Diabetes, obesity & metabolism.
[21] S. Ruberg,et al. Estimands in clinical trials – broadening the perspective , 2017, Statistics in medicine.
[22] Tyler J VanderWeele,et al. A simple method for principal strata effects when the outcome has been truncated due to death. , 2011, American journal of epidemiology.
[23] Y. Lou,et al. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data , 2018, Journal of biopharmaceutical statistics.
[24] D. Pauler,et al. An Estimator for Treatment Comparisons among Survivors in Randomized Trials , 2005, Biometrics.
[25] 임재영,et al. BMI(Body Mass Index)가 소득에 미치는 영향 , 2012 .
[26] Baldur P Magnusson,et al. Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by post-randomization events , 2018, 1809.03741.
[27] T. Permutt. Effects in Adherent Subjects , 2018, Statistics in Biopharmaceutical Research.